Doxapram (hydrochloride hydrate)

Doxapram hydrochloride hydrate is a respiratory stimulant. Doxapram hydrochloride hydrate increases breathing rate and depth by acting on the brain's respiratory centers and peripheral chemoreceptors. Doxapram hydrochloride hydrate inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50s of 410 nM, 37 μM, 9 μM, respectively. Doxapram hydrochloride hydrate inhibits the Ca²⁺-activated potassium current (IC50 ≈ 13 μM) and Ca²⁺-independent potassium current (IC50 ≈ 20 μM) in type I cells of the carotid body. Doxapram hydrochloride hydrate significantly prolongs the effective refractory period of the atrium and has an anti-arrhythmic effect. Doxapram hydrochloride hydrate can be used for the study of respiratory depression such as post-anesthesia respiratory depression, chronic obstructive pulmonary disease and apnea of prematurity[1][2][3][4][5][6].

Product Specifications

CAS Number

[7081-53-0]

UNSPSC

12352005

Hazard Statement

H301

Target

Potassium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/doxapram-hydrochloride-hydrate.html

Purity

99.28

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 25 mg/mL (ultrasonic)

Smiles

O=C1N(CC)CC(CCN2CCOCC2)C1(C3=CC=CC=C3)C4=CC=CC=C4.Cl.O

Molecular Formula

C24H33ClN2O3

Molecular Weight

432.98

Precautions

H301

References & Citations

[1]Cotten JF, et al. The ventilatory stimulant doxapram inhibits TASK tandem pore (K2P) potassium channel function but does not affect minimum alveolar anesthetic concentration. Anesth Analg, 2006, 102 (3), 779-785.|[2]Anderson-Beck, R., et al., Doxapram stimulates dopamine release from the intact rat carotid body in vitro. Neurosci Lett, 1995. 187 (1) : p. 25-8.|[3]Peers, C., Effects of doxapram on ionic currents recorded in isolated type I cells of the neonatal rat carotid body. Brain Res, 1991. 568 (1-2) : p. 116-22.|[4]Wiedmann F, et al. Treatment of atrial fibrillation with doxapram: TASK-1 potassium channel inhibition as a novel pharmacological strategy. Cardiovasc Res. 2022 Jun 22;118 (7) :1728-1741.|[5]Vliegenthart RJ, et al. Doxapram Treatment for Apnea of Prematurity: A Systematic Review. Neonatology. 2017;111 (2) :162-171. doi: 10.1159/000448941. Epub 2016 Oct 20. |[6]Yost CS. A new look at the respiratory stimulant doxapram. CNS Drug Rev. 2006 Fall-Winter;12 (3-4) :236-49.